---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-007850"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:51:26.662742+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q4 revenue up 109% to $7.3M; ET-400 NDA submission planned Q2 2024

## Summary
- Q4 2023 product sales & royalty revenue $7.3M, up 109% YoY; full-year revenue $26.1M (+132%).
- Net loss of $2.3M ($0.09/share) in Q4 vs net income of $0.9M in Q4 2022; operating cash flow positive $0.4M.
- ET-400 (oral hydrocortisone) passed pivotal bioequivalence study; NDA submission expected Q2 2024.
- ET-600 passed pilot bioequivalence study; pivotal study planned H2 2024, NDA in early 2025.
- Launched Nitisinone capsules in Feb 2024; sampling program for ALKINDI SPRINKLE went live.

## SEC filing metadata
- accession: 0001437749-24-007850
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007850/0001437749-24-007850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007850/eton20231213_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-007850
- JSON: https://secwatch.observer/filing/0001437749-24-007850.json
- Plain text: https://secwatch.observer/filing/0001437749-24-007850.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2023 results: revenue $7.3 million, net income $2.3 million, EPS $0.09 per basic and diluted share.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $7.3 million
  - Net income: $2.3 million
  - EPS: $0.09 per basic and diluted share
  - Result: reported results
  source text: Net revenue: Net product sales and royalty revenues for the fourth quarter of 2023 increased by 109% to $7.3 million compared to $3.5 million in the prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774924007850/0001437749-24-007850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.